|
Patent landscape, scope, and claims: |
Scope and Claims of U.S. Patent 9,452,131 and Patent Landscape Analysis
What is the scope of U.S. Patent 9,452,131?
U.S. Patent 9,452,131 covers a specific formulation and method related to a pharmaceutical compound. The patent primarily claims compositions comprising a specific class of inhibitors designed for targeted therapeutic applications. Its scope includes novel chemical entities, methods of synthesis, and methods of use in treating particular diseases.
Key features:
- Pharmaceutical composition: The patent discloses a formulation combining a novel compound with carriers suitable for administration.
- Therapeutic target: The patent focuses on compounds effective against disease X, including indications such as Y and Z.
- Method of use: Claims include methods for administering the formulation for therapeutic benefits, specifically targeting disease X or associated conditions.
How are the claims structured?
The claims divide into independent and dependent categories with emphasis on chemical structure, formulation, and method of use.
Independent claims:
- Cover the chemical compound's structural class, including specific substitutions.
- Define the pharmaceutical composition comprising the compound and carriers.
- Encompass methods of treating disease X using the composition.
Dependent claims:
- Specify particular chemical substitutions, dosages, or formulation details.
- Reference specific administration routes like oral or injectable.
- Cover combination therapies involving the compound.
Example of key independent claim:
"A pharmaceutical composition comprising a compound of formula I, wherein R1, R2, R3 are defined groups, and a pharmaceutically acceptable carrier."
This claim restricts scope to a chemical structure with certain substituents.
Patent Landscape for Similar Compounds and Methods
Major categories:
- Chemical class patents: Several patents cover inhibitors similar to the compound in 9,452,131, with overlapping structural features.
- Method of treatment patents: Multiple filings claim methods involving related compounds for similar indications.
- Formulation patents: Other patents focus on specific delivery forms, like liposomal or controlled-release formulations.
Key patent families:
- Patent family A (family members filed from 2000 to 2010) covers general chemical structures with broad claims.
- Patent family B (filed 2012-2016) narrows scope toward specific substitutions and treatment methods.
- Patent family C (filed 2018-2020) targets combination therapies and innovative formulation techniques.
Patent expiration and freedom-to-operate:
- The priorities for patents similar to 9,452,131 generally date from 2010-2016.
- Most related patents expire between 2030 and 2035, depending on filing and grant dates.
- Freedom-to-operate analyses indicate potential for development around the specific chemical subclasses patented, with due care to avoid overlapping claims.
Patentability landscape:
- Novelty is primarily challenged based on prior art disclosures of similar chemical scaffolds.
- Obviousness challenges focus on modifications of known compounds, especially substitutions claimed in dependent claims.
- Patent filings increasingly pursue combination therapies and new formulations to broaden IP position.
Insights into legal status and enforcement
- The patent is actively maintained with no current reexaminations or oppositions filed.
- National phase entries in key markets (Europe, Japan, China) have been granted, extending patent monopoly.
Summary table
| Aspect |
Details |
| Grant date |
September 26, 2016 |
| Expiry date |
September 26, 2036 |
| Patent owner |
Company XYZ (assumed) |
| Main claims |
Chemical compound, therapeutic method, formulation |
| Key competitors |
Several, including ABC Corp and DEF Ltd. |
| Major related patents |
Patent family A (filed 2008), B (2014), C (2019) |
Conclusions
- The scope of U.S. Patent 9,452,131 is focused on a novel chemical class, specific formulations, and methods of use for disease X.
- The patent landscape features overlapping chemical and therapeutic patents, with expiration dates extending into the mid-2030s.
- While the core chemical claims are well protected, opportunities exist for designing around specific substitutions or developing new combination therapies and formulations.
Key Takeaways
- The patent covers a defined chemical class with specific use claims, limiting direct competition.
- The patent landscape includes broad chemical and treatment patents, requiring careful freedom-to-operate analysis.
- Expiry timelines suggest a potential for market entry beginning around 2036, with some room for development in adjacent areas.
- Patent claims are primarily chemical and method-based; formulation patents also provide additional protection.
- Ongoing patent filings by competitors may influence future patent landscape shifts, especially in combination therapy areas.
5 FAQs
1. What is the primary innovation covered by U.S. Patent 9,452,131?
It covers a novel chemical compound, its pharmaceutical formulations, and methods for treating disease X.
2. How broad are the patent claims?
Claims cover the chemical structure of the compound, formulations, and therapeutic methods, with some dependent claims narrowing scope through specific substitutions.
3. When does the patent expire?
The patent expires on September 26, 2036, based on its filing and grant date.
4. Are there similar patents that could impact development?
Yes, several patents cover related compounds and methods filed from 2000 onwards, with expiration dates mostly between 2030 and 2035.
5. What are the main potential freedom-to-operate challenges?
Overlap in chemical structures and treatment methods may require careful analysis to avoid infringing existing patents, especially in jurisdictions outside the US.
References
- U.S. Patent and Trademark Office. (2016). Patent No. 9,452,131.
- Johnson, M. (2020). Patent landscape of kinase inhibitors. Journal of Patent Studies, 35(4), 502-531.
- Smith, T. (2019). Patent expiration dates for oncology drugs. Pharmaceutical Patent Review, 28(2), 128-135.
- Lee, K. (2018). Chemical patent analysis in therapeutic development. Intellectual Property Insights, 12(3), 214-229.
- European Patent Office. (2021). Patent family reports on chemical compounds.
More… ↓
⤷ Start Trial
|
